Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

57.87USD
4:03pm EDT
Change (% chg)

$0.20 (+0.35%)
Prev Close
$57.67
Open
$57.63
Day's High
$58.16
Day's Low
$57.43
Volume
1,088,005
Avg. Vol
1,984,500
52-wk High
$60.44
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb's Orencia receives FDA approval
Thursday, 6 Jul 2017 07:30am EDT 

July 6 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb's Orencia (abatacept) receives FDA approval for treatment of active psoriatic arthritis (PSA) in adults.Bristol-Myers Squibb Co - Orencia is approved and available in both intravenous and subcutaneous injection formulations.  Full Article

Bristol-Myers Squibb announces expiration of cash tender offer
Wednesday, 21 Jun 2017 06:59am EDT 

June 21 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb announces the expiration of its cash tender offer.Bristol-Myers Squibb announces the expiration of its cash tender offer.Bristol-Myers -approximately $337.0 million in aggregate principal amount of notes subject to tender offer were validly tendered and not validly withdrawn.  Full Article

Bristol-Myers announces results from extended follow-up data evaluating opdivo
Friday, 16 Jun 2017 06:58am EDT 

June 16 (Reuters) - Bristol-Myers Squibb Co ::Extended follow-up data evaluating opdivo (nivolumab) shows durable response in adult patients with relapsed or progressed classical hodgkin lymphoma.Bristol-Myers Squibb- ‍results show overall response rates of 65%/greater with median follow-up of at least 16 months.Bristol-Myers says as per extended follow-up data evaluating opdivo​, ‍across cohorts, median overall survival not reached, 40% of patients remained on treatment.  Full Article

Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co
Friday, 16 Jun 2017 04:35am EDT 

June 16 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb to sell manufacturing facility in swords, Ireland to SK Biotek Co., Ltd..Bristol-Myers - to sell small molecule active pharmaceutical ingredient manufacturing facility in swords, Ireland, to SK Biotek.Bristol-Myers Squibb Co - transaction has been approved by boards of directors of both companies.  Full Article

Bristol-Myers Squibb announces cash tender offer
Wednesday, 14 Jun 2017 08:40am EDT 

June 14 (Reuters) - Bristol-myers Squibb Co :Announces cash tender offer for any and all of certain of its outstanding debt securities.Commenced a cash tender offer for any and all of its 5.875 pct notes due 2036, 6.125 pct notes due 2038 and 6.875 pct debentures due 2097.Expiration date of tender offer is 5:00 p.m., New York City time, on June 20, 2017.  Full Article

Bristol-Myers Squibb declares quarterly dividend of $0.39/shr
Tuesday, 13 Jun 2017 04:05pm EDT 

June 13 (Reuters) - Bristol-myers Squibb Co ::Bristol-Myers Squibb Co says declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation.  Full Article

Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Monday, 5 Jun 2017 04:05pm EDT 

June 5 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer.Entered into a clinical research collaboration with Novartis.  Full Article

Incyte says epacadostat, Bristol-Myers' Opdivo combo data positive in head and neck cancer patients
Monday, 5 Jun 2017 07:30am EDT 

June 5 (Reuters) - Incyte Corp :Clinical trial data for combination of epacadostat and opdivo® (nivolumab) demonstrate durable clinical responses in patients with melanoma and head and neck cancer.Incyte corp - combination of ido1 enzyme inhibition plus opdivo was generally well-tolerated in patients with select advanced solid tumors.  Full Article

European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)
Friday, 2 Jun 2017 05:00pm EDT 

June 2 (Reuters) - Bristol-Myers Squibb Co ::European Commission approves Bristol-Myers Squibb’s opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.Bristol-Myers Squibb Co - ‍opdivo is now approved in european union for eight indications in six distinct tumor types​.  Full Article

Bristol-Myers announces first disclosure of data from a cohort of phase 1/2 CheckMate-358 study
Friday, 2 Jun 2017 06:59am EDT 

June 2 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers - Announces first disclosure of data from a cohort of phase 1/2 CheckMate -358 study.Bristol-Myers Squibb Co says median duration of response has not been reached after 6 months of follow-up.Bristol-Myers Squibb Co - Grade 3/4 treatment-related adverse events occurred in 12.5% of patients in phase 1/2 checkmate -358 study evaluating Opdivo.Bristol-Myers - Opdivo showed safety profile consistent with previous results seen with Opdivo monotherapy in other tumor types, in CheckMate -358​ study.Bristol-Myers - ‍overall response rate of 26.3% in patients with cervical cancer regardless of PD-l1, HPV status and number of prior systemic therapies​.  Full Article

Photo

Wall Street ends up but off highs after Trump announcement, Fed minutes

NEW YORK U.S. stocks ended slightly firmer on Wednesday but off the day's highs as worries mounted over President Donald Trump's agenda and minutes from the latest Federal Reserve meeting suggested policymakers are worried about weak inflation. | Video